文献速递冠心病心力衰竭与心肌病

首次急性冠脉综合征前接受他汀治疗可降低心力衰竭与死亡风险

Reduced Heart Failure and Mortality in Patients Receiving Statin Therapy Before Initial Acute Coronary Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

研究基于ISACS注册中14,542例无既往ASCVD事件的白色人种ACS患者,采用逆概率加权比较既往他汀使用者与非使用者。结果显示既往他汀治疗与入院时急性心衰发生率显著降低相关(绝对风险降低4.3%,RR 0.72,95%CI 0.62-0.83),且在入院时急性心衰患者中与30天全因死亡率降低相关(绝对风险降低5.2%,RR 0.71,95%CI 0.50-0.99)。

要点

  • ACS首次表现者中,既往他汀治疗与入院急性心衰风险降低相关(RR 0.72)。
  • 该关联不受年龄(40-75岁与老年,交互P=0.27)和性别(交互P=0.22)影响。
  • 入院时急性心衰患者中,既往他汀治疗与30天死亡风险降低相关(RR 0.71)。

核心结论

  • 在ACS作为ASCVD首次表现的成人中,既往他汀治疗与急性心衰风险降低及急性心衰后生存改善相关。

研究设计与样本

  • 数据来自国际急性冠脉综合征调查档案(ISACS Archives;NCT04008173)。
  • 纳入14,542例无既往ASCVD事件的白色人种ACS患者,采用逆概率加权模型比较既往他汀使用者与非使用者。

主要发现

  • 既往他汀治疗与入院时急性心衰发生率显著降低相关,绝对风险降低4.3%,RR 0.72(95%CI 0.62-0.83)。
  • 该关联在年轻(40-75岁)与老年患者间无显著交互(交互P=0.27),性别间亦无显著交互(交互P=0.22)。
  • 在入院时急性心衰患者亚组中,既往他汀治疗与30天全因死亡率降低相关,绝对风险降低5.2%,RR 0.71(95%CI 0.50-0.99)。

临床怎么用

  • 对于尚无ASCVD事件的人群,既往他汀治疗可能降低首次ACS时急性心衰发生风险及心衰后短期死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is uncertainty regarding the impact of statins on the risk of atherosclerotic cardiovascular disease (ASCVD) and its major complication, acute heart failure (AHF). OBJECTIVES: The aim of this study was to investigate whether previous statin therapy translates into lower AHF events and improved survival from AHF among patients presenting with an acute coronary syndrome (ACS) as a first manifestation of ASCVD. METHODS: Data were drawn from the International Survey of Acute Coronary Syndromes Archives. The study participants consisted of 14,542 Caucasian patients presenting with ACS without previous ASCVD events. Statin users before the index event were compared with nonusers by using inverse probability weighting models. Estimates were compared by test of interaction on the log scale. Main outcome measures were the incidence of AHF according to Killip class and the rate of 30-day all-cause mortality in patients presenting with AHF. RESULTS: Previous statin therapy was associated with a significantly decreased rate of AHF on admission (4.3% absolute risk reduction; risk ratio [RR]: 0.72; 95% CI: 0.62-0.83) regardless of younger (40-75 years) or older age (interaction P = 0.27) and sex (interaction P = 0.22). Moreover, previous statin therapy predicted a lower risk of 30-day mortality in the subset of patients presenting with AHF on admission (5.2 % absolute risk reduction; RR: 0.71; 95% CI: 0.50-0.99). CONCLUSIONS: Among adults presenting with ACS as a first manifestation of ASCVD, previous statin therapy is associated with a reduced risk of AHF and improved survival from AHF. (International Survey of Acute Coronary Syndromes [ISACS] Archives; NCT04008173).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bugiardini, Yoon, Mendieta, et al. Reduced Heart Failure and Mortality in Patients Receiving Statin Therapy Before Initial Acute Coronary Syndrome. J Am Coll Cardiol. 2022. PMID: 35589164. doi:10.1016/j.jacc.2022.03.354

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。